Showing results (441-450 of 531) with videos related to
Sort By:
Pageof 54
Blood|June 22, 2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphomaJakub Svoboda, Susan R Rheingold, Saar I Gill, et al.Journal of Hematology & Oncology|April 21, 2024
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucelGuido Ghilardi, Luca Paruzzo, Vrutti Patel, et al.Transplantation and Cellular Therapy|July 19, 2022
Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell LymphomasPeter A Riedell, Wei-Ting Hwang, Loretta J Nastoupil, et al.American Journal of Hematology|March 20, 2026
Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary AnalysisNancy L Bartlett, Laurie H Sehn, Sarit Assouline, et al.Blood Advances|August 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphomaGilles Salles, Stephen J Schuster, Martin Dreyling, et al.Medical Oncology (Northwood, London, England)|January 5, 2000
Stem cell transplantation for metastatic breast cancer: analysis of tumor contaminationE A Stadtmauer, D E Tsai, C J Sickles, et al.The Lancet. Haematology|February 25, 2021
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trialJeff P Sharman, Danielle M Brander, Anthony R Mato, et al.Bone Marrow Transplantation|October 6, 2005
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphomaC Andreadis, S J Schuster, E A Chong, et al.The New England Journal of Medicine|December 9, 2014
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphomaStephen M Ansell, Alexander M Lesokhin, Ivan Borrello, et al.Blood Advances|February 20, 2020
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphomaRichard T Maziarz, Edmund K Waller, Ulrich Jaeger, et al.Pageof 54